Results 201 to 210 of about 22,482 (226)

Effect of aflibercept on proliferative vitreoretinopathy: Proteomic analysis in an experimental animal model

Experimental Eye Research, 2021
Aylin Kanli, Isil Uslubaş
exaly  

Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Keiko Kataoka, Kanako Itagaki, Nozumu Hashiya, Sorako Wakugawa, Koji Tanaka, Makiko Nakayama, Akiko Yamamoto, Ryo Mukai, Jyunichiro Honjyo, Ichiro Maruko, Moeko Kawai, Yasunori Miyara, Nobuhiro Terao, Yu Wakatsuki, Hajime Onoe, Ryusaburo Mori, Hideki Koizumi, Tetsuju Sekiryu, Tomohiro Iida, A. A. Okada, for Japan AMD Research Consortium   +20 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly, 2015
  +4 more sources

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

Biomedicines, 2021
Kenji Kashiwagi, Yoichi Sakurada, Mio Matsubara   +2 more
exaly  

High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept

Journal of Vitreoretinal Diseases, 2023
Jared S Nielsen
exaly  

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Ophthalmology (Rochester, Minn.), 2012
J. Heier, David M. Brown, V. Chong, J. Korobelnik, P. Kaiser, Q. Nguyen, B. Kirchhof, A. Ho, Y. Ogura, G. Yancopoulos, N. Stahl, R. Vitti, Alyson J. Berliner, Yuhwen Soo, Majid Anderesi, Georg Groetzbach, B. Sommerauer, R. Sandbrink, C. Simader, U. Schmidt-Erfurth   +19 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly, 2020
openaire   +1 more source

A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously

Analytical and Bioanalytical Chemistry, 2020
Fei Yu, Liu Wanhui, Fangjie Liu
exaly  

Aflibercept

Nature Reviews Drug Discovery, 2012
Michael W. Stewart, Seden Grippon, Peter Kirkpatrick   +2 more
openaire   +1 more source

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Gynecologic Oncology, 2012
Robert L Coleman, R Katherine Alpaugh, Michael W Sill   +2 more
exaly